MétaCan
Menu
Back to cohort
Record W4389243191 · doi:10.1182/blood-2023-188259

<i>Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions</i>

2023· article· en· W4389243191 on OpenAlexaffabout
Natasha Szuber, Steve Dagenais-Bellefeuille, Mégane Tanguay, Awatef Shehabeldeen, Saima Ahmed, Michaël Harnois, Jaroslav F. Prchal, Harold J. Olney, Lambert Busque, Shireen Sirhan

Bibliographic record

VenueBlood · 2023
Typearticle
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsCentre Hospitalier de l’Université de MontréalMcGill UniversityJewish General HospitalConcordia UniversitySt Mary's Hospital CentreUniversité de Montréal
Fundersnot available
KeywordsMedicineEssential thrombocythemiaPerioperativeMyelofibrosisPopulationPolycythemia veraSurgeryThrombosisMyeloproliferative neoplasmVenous thrombosisInternal medicine

Abstract

fetched live from OpenAlex

Background: Classic myeloproliferative neoplasms (MPN) polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by concurrent risk of thrombotic and hemorrhagic complications. These risks are reported to be further compounded perioperatively ( Blood, 2008), though scarce contemporary data exist. Further, the lack of evidence-based guidelines leads to heterogeneous management. The objective of this study was to comparatively assess perioperative complication rates (thrombotic, hemorrhagic, and survival) and management practices in a large MPN population. Methods: Consecutive surgical interventions in patients with WHO-defined PV, ET and MF recruited from the Quebec MPN Research Group Registry (6 centers; between 1986-2023) were analyzed. Endpoints (90 days post-surgery) and surgical definitions were per convention. Standard statistics were used (JMP® Pro 14.1.0 software; SAS Institute, Cary, NC, USA). Results: A total of 354 procedures were captured in 184 patients: PV, n=87 (47%); ET, n=66 (36%); MF, n=31 (17%). Cardiovascular risks were balanced; previous venous thrombosis was enriched in PV (p=0.04; Table 1A). Major surgeries were performed in 45 cases (30%), primarily PV (p=0.004); most being general (69%) (Table 1B). Interventions were urgent in 41 cases (28%); 49 (42%) of 195 evaluable were under general anesthesia. The majority of PV/ET subjects continued antiplatelet and cytoreductive agents peri-intervention, though cytoreduction was stopped in 12-22%. Thromboprophylaxis was administered in n=42 (23%). Surgical bleeding occurred in n=8 (2%). At 90-day follow-up, arterial/venous thrombosis occurred each in n=3 (1%), hemorrhage in n=25 (8%), and death in n=4 (1%). Overall complication rate was 12% (n=40). PV patients displayed significantly higher rates of surgical bleeding (6%; p=0.0006) and perioperative hemorrhage (13%; p=0.04). Factors impacting 90-day surgical outcomes: Hemorrhage-free survival (HFS): PV: General anaesthesia (p=0.04) and antithrombotic prophylaxis (p=0.05) negatively impacted HFS on multivariate testing (Table 2). ET: Driver mutation status CALR vs JAK2 (HR 24.6; 95% CI 1.2-504; p=0.05) and urgent interventions (HR 11.5; 95% CI 0.93-144; p=0.03) emerged as independent predictors for HFS. MF: Discontinuation of antiplatelet agents perioperatively was the sole factor impacting HFS (p=0.01). Perioperative complication-free survival (CFS; composite endpoint): PV: While several factors were significant on univariate testing (procedure, leukocytosis, ruxolitinib exposure, cytoreduction modification, thromboprophylaxis), multivariate testing disclosed only lower hematocrit (< 35%; p=0.05) to impact complication rates. ET: Urgent (p<0.0001) and major procedures (p=0.009), thromboprophylaxis use (p=0.001), platelet count > 450 x 10 9/L (p=0.02), and absence of antiplatelet (p=0.02) were significant independent predictors of CFS. MF: Antiplatelet discontinuation (HR 6.5; 95% CI 0.8-50.4; p=0.02), nature of cytoreduction (ruxolitinib vs hydrea; p=0.04) and cytoreduction discontinuation pre-operatively (p=0.006) negatively impacted CFS on multivariate analysis. Limited informative events for thrombosis/survival precluded analyses. Conclusions: This is, to our knowledge, the largest and most contemporary analysis of surgical procedures in patients with MPN. Firstly, it confirms prevalent bleeding perioperatively, though balanced by fewer thrombotic events, calling for further study of thromboprophylaxis/antiplatelet practices in this setting. Second, it discloses key management patterns, notably routine discontinuation of cytoreduction, which had a detrimental impact on outcomes. Third, correlation of uncontrolled platelets and overzealous hematocrit control with higher complication rates in ET and PV, respectively, underscores importance of judicious target control. Further, CALR driver mutation status associated with bleeding risk in ET, independent of platelet count, suggesting additional contributing mechanisms. Finally, ruxolitinib use was an independent predictor of perioperative complications in MF, though this may reflect skewing towards higher-risk populations. Further studies will be required to validate findings, with this data serving as a preliminary signal for awareness of risk and reappraisal of management strategies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.023
Threshold uncertainty score0.045

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.277
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueBloodSame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207